Nuvalent | Investor Presentation Deck

Slide schematic 7/7

disclaimer 1/1 list 3/3 source-note 1/1 title 2/2

Components 7

disclaimer bullet bullet bullet source-note action-title headline

Tools 1

list/bullet: 2L column: Current SOC Lorlatinib, ~50% single mutations, >60% CNS disease. Opportunity to differentiate with deep, durable responses and TRK-sparing profile.

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

market-segmentation-pyramid 80%

Segmentation by treatment line (1L, 2L, 3L+)

Find anything

The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and map the drug's value proposition to each.